drugset / Trial / NCT02735707

Summary

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Timeline

Start
2016-04-11
Primary completion
2026-02
Completion
2028-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified
Subject Anakinra Protein / enzyme biologic 100 mg Intravenous
Subject Apremilast Small molecule 30 mg
Subject Aspirin Small molecule 75 mg
Subject Aspirin Small molecule 100 mg
Subject Azithromycin Small molecule Intravenous
Subject Baloxavir Marboxil Unknown
Subject Baricitinib Small molecule
Subject Candesartan Unknown
Subject Captopril Small molecule
Subject Ceftaroline Other / unclassified
Subject Ceftriaxone Other / unclassified
Subject Clarithromycin Small molecule Intravenous
Subject Clopidogrel Small molecule 75 mg
Subject Convalescent Plasma Protein / enzyme biologic
Subject Cysteamine Unknown 5 mg/kg
Subject Dexamethasone Small molecule 6 mg Intravenous
Subject Enalapril Other / unclassified
Subject Eritoran Small molecule 6.56 mg Intravenous
Subject Heparin Other / unclassified
Subject Hydrocortisone Other / unclassified 50 mg Intravenous
Subject Hydrocortisone Other / unclassified 100 mg Intravenous
Subject Hydroxychloroquine Small molecule 400 mg Oral
Subject Imatinib Small molecule 400 mg Oral
Subject Interferon beta-1a Protein / enzyme biologic 10 ug Intravenous
Subject Irbesartan Small molecule
Subject Ivermectin Small molecule 0.2 mg/kg Oral
Subject LISINOPRIL ANHYDROUS Small molecule
Subject Levofloxacin Small molecule
Subject Lopinavir Other / unclassified 400 mg
Subject Losartan Other / unclassified
Subject Moxifloxacin Small molecule
Subject Nirmatrelvir Small molecule
Subject Olmesartan Other / unclassified
Subject Oseltamivir Small molecule
Subject Perindopril Small molecule
Subject Prasugrel Small molecule 10 mg
Subject Propagermanium Unknown 120 mg Oral
Subject Ramipril Small molecule
Subject Remdesivir Small molecule 100 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified
Subject Sarilumab Monoclonal antibody 400 mg Intravenous
Subject Simvastatin Small molecule 80 mg Oral
Subject Telmisartan Other / unclassified
Subject Ticagrelor Small molecule 60 mg
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous
Subject Valsartan Small molecule
Subject Vitamin C Other / unclassified 50 mg/kg Intravenous
Subject roxithromycin Small molecule
Subject trandolapril Small molecule

Indications